Abstract：【Objective】To explore the clinical efficacy of Shensong Yangxin Capsules combined with Deanxit in the treatment of patients with depression after percutaneous coronary intervention (PCI) for coronary heart disease (CHD). 【Methods】A total of 102 patients with depression after PCI for CHD admitted to our hospital from June 2022 to December 2024 were selected. According to the random number table method, they were divided into the observation group (treated with Deanxit + Shensong Yangxin Capsules) and the control group (treated with Deanxit), with 51 cases in each group. After 3 months of treatment, the TCM syndrome scores, depression status, and clinical efficacy of the two groups were evaluated and compared. The neurotransmitter factors [brain-derived neurotrophic factor (BDNF), 5-hydroxytryptamine (5-HT)], cardiac function indicators [left ventricular end-diastolic diameter (LVEDD), left ventricular ejection fraction (LVEF)], and the occurrence of adverse reactions were also compared between the two groups. 【Results】The total clinical effective rate of the observation group was 94.12% (48/51), which was higher than 80.39% (41/51) of the control group, and the difference was statistically significant (P<0.05). At 1 month and 3 months after treatment, the serum levels of BDNF and 5-HT in both groups were higher than those before treatment, and the observation group was higher than the control group, with statistically significant differences (P<0.05). At 1 month and 3 months after treatment, the LVEF of both groups was higher than that before treatment, and the LVEDD was lower than that before treatment; the LVEF of the observation group was higher than that of the control group, and the LVEDD was lower than that of the control group, with statistically significant differences (P<0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】Shensong Yangxin Capsules combined with Deanxit has a good clinical efficacy in the treatment of depression after PCI for CHD. It can significantly improve the clinical symptoms of patients, enhance the levels of neurotransmitter factors and cardiac function, and has good safety.
齐彦威. 参松养心胶囊联合黛力新治疗冠心病PCI术后抑郁患者的临床疗效[J]. 医学临床研究, 2025, 42(8): 1370-1373.
QI Yanwei. Clinical Efficacy of Shensong Yangxin Capsules Combined with Deanxit in the Treatment of Patients with Depression after PCI for Coronary Heart Disease. JOURNAL OF CLINICAL RESEARCH, 2025, 42(8): 1370-1373.
[1] 中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2021概要[J].中国循环杂志,2022,37 (6):553-578. [2] MORONI F, BRILAKIS E S, AZZALINI L. Chronic total occlusion percutaneous coronary intervention: managing perforation complications[J].Expert Rev Cardiovasc Ther,2021, 19(1):71-87. [3] 王文锋,丁守坤.艾司西酞普兰对冠心病伴焦虑、抑郁患者炎症因子水平及血管内皮功能的影响[J].医学临床研究,2024,41(3):424-427. [4] 谢伟. 黛力新对慢性心衰并发抑郁症患者心脏功能及血浆NT-proBNP水平的影响[J].医学临床研究, 2016, 33(6):1111-1113. [5] 抑郁障碍中西医整合诊治专家共识组, 中国民族医药学会神志病分会. 抑郁障碍中西医整合专家共识[J].中国医药导报, 2021, 18(6):4-12. [6] 刘雅琴,李淑玲,祁泉.参松养心胶囊治疗老年冠心病室性早搏气阴两虚、心络瘀阻型患者临床观察[J].西部中医药,2024,37(4):139-141. [7] BARBANO A C, VAN DER MEI W F, DEROON-CASSINI T A, et al. Differentiating PTSD from anxiety and depression: Lessons from the ICD-11 PTSD diagnostic criteria[J].Depress Anxiety,2019, 36(6):490-498. [8] 中华中医药学会介入心脏病学专家委员会. 经皮冠状动脉介入治疗(PCI)手术前后抑郁和(或)焦虑中医诊疗专家共识[J].中医杂志, 2015, 56(4):357-360. [9] 陈昊天, 陈理. 冠心病PCI术后焦虑抑郁的中西医研究进展[J].中国疗养医学,2022,31(9):941-944. [10] 周华东,龙贤,孔德娇,等.中医药治疗 PCI 术后焦虑抑郁状态疗效的Meta分析[J].中医药临床杂志,2021,33(3):455-461. [11] KHANDAKER G M, ZUBER V, REES J M B, et al. Shared mechanisms between coronary heart disease and depression: findings from a large UK general population-based cohort[J].Mol Psychiatry,2020, 25(7):1477-1486. [12] WANG D D, DAI F, LIU W J, et al. Longitudinal change and prognostic value of anxiety and depression in coronary heart disease patients[J].Ir J Med Sci,2021, 190(1):107-116. [13] RUNA A, BAO Q L, SAI Y C, et al. Clinical observation of warming acupuncture and moxibustion at the temples combined with deanxit in the treatment of tension headache with anxiety and depression: a retrospective study[J].Ann Palliat Med,2021, 10(5):5541-5548. [14] 常宁,胡佳,赵刘乐.草酸艾司西酞普兰联合参松养心胶囊治疗冠心病伴抑郁症的临床效果[J].临床合理用药,2021,14(12):47-48. [15] 左惠丽,段秀芳.参松养心胶囊与草酸艾司西酞普兰联用治疗冠心病伴抑郁症的疗效观察[J].基础医学论坛,2019,14(12):1449-1450. [16] 王玉, 杨雪, 夏鹏飞, 等. 酸枣仁汤化学成分、药理作用、临床应用的研究进展及质量标志物的预测分析[J].中国中药杂志, 2020, 45(12):2765-2771. [17] 王波, 王天磊, 谭春凤, 等. 醒神启闭针刺法对脑卒中后抑郁的疗效及5-HT、NGF、IL-23的影响[J].中华中医药学刊, 2020, 38(12):84-86.
2025, Vol. 42 
